title: Radiosynoviorthesis of knees by means of 166Ho-holmium-boro-macroaggregates.
abstract: The aim of this study was to evaluate adverse and therapeutic effects of applicated holmium-boro-macroaggregates (HBMAs) in the radiosynoviorthesis (RSO) of knees in patients suffering from chronic synovitis. We started RSO of the knees by means of a new radiopharmaceutical (RF) HBMA in patients with gonarthrosis, rheumatoid arthritis, chronic synovitis, psoriatic arthritis, and gout arthropathy. Seventeen (17) intra-articular injections were performed in 15 patients who were receiving a mean activity of 972 MBq (range, 904-1057) of 166Ho-HBMA. Patient inclusion to the study followed a series of inclusion and exclusion criterions. The patients were hospitalized for 3 days. Side-effects were evaluated during their hospital stay and again after 6-8 weeks. Static scintigraphy of knee joints and measurements of blood radioactivity were performed. Therapeutic effects were evaluated after 6-8 weeks and at 6 months. In 2 hours and 2 days following the application, we proved, by means of knee and inguinal scintigraphy, only insignificant radiopharmaceutical leakage from the joint cavity to the inguinal lymph nodes in 4 patients. In the treated patients, no serious adverse effects occurred. Nine (9) patients were without complaints, 4 patients had slight knee exudation, and 2 patients had great exudation. Therapeutic effects were as follows: 2 patients were without pain, 9 were with lower pain, 3 were with the same pain, and 1 patient was with increased pain. Joint motion was improved in 7 patients, remained the same in 7 patients, and was impaired in 1 patient. Analgesics consumption was lower in 5 patients, the same in 9 patients, and greater in 1 patient. Knee exudation was absent in 2 patients, lower in 4 patients, the same in 6 patients, and greater in 3 patients. In 3 patients it was necessary to do surgical RSO. This RF can extend the range of clinically used radiopharmaceuticals for RSO and to supplement space between 90Y with high energy and 186Re with 169Er with lower beta energy. The energy of 166Ho is suitable for great and medium joints (i.e., knees, hips, shoulders, elbows, wrists, and ankles).
authors.affiliation: Department of Nuclear Medicine, University Hospital, Ostrava-Poruba, Czech Republic. otakar.kraft@fnspo.cz
authors.forename: Otakar
authors.initials: O
authors.lastname: Kraft
authors.forename: Richard
authors.initials: R
authors.lastname: Kaspárek
authors.forename: Vojtech
authors.initials: V
authors.lastname: Ullmann
authors.forename: Frantisek
authors.initials: F
authors.lastname: Melichar
authors.forename: Martin
authors.initials: M
authors.lastname: Kropácek
authors.forename: Marcela
authors.initials: M
authors.lastname: Mirzajevova
mesh_terms: D000293:Adolescent; D000328:Adult; D005260:Female; D006695:Holmium / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D007717:Knee / Q000473:pathology* / Q000528:radiation effects*; D008297:Male; D008875:Middle Aged; D013585:Synovitis / Q000473:pathology* / Q000532:radiotherapy*; D013997:Time Factors
chemical_list: D006695:Holmium